Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
- PMID: 40450658
- DOI: 10.1056/NEJMoa2502760
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Abstract
Background: Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking.
Methods: In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program (exercise group) or to receive health-education materials alone (health-education group) over a 3-year period. The primary end point was disease-free survival.
Results: From 2009 through 2024, a total of 889 patients underwent randomization to the exercise group (445 patients) or the health-education group (444 patients). At a median follow-up of 7.9 years, disease-free survival was significantly longer in the exercise group than in the health-education group (hazard ratio for disease recurrence, new primary cancer, or death, 0.72; 95% confidence interval [CI], 0.55 to 0.94; P = 0.02). The 5-year disease-free survival was 80.3% in the exercise group and 73.9% in the health-education group (difference, 6.4 percentage points; 95% CI, 0.6 to 12.2). Results support longer overall survival in the exercise group than in the health-education group (hazard ratio for death, 0.63; 95% CI, 0.43 to 0.94). The 8-year overall survival was 90.3% in the exercise group and 83.2% in the health-education group (difference, 7.1 percentage points; 95% CI, 1.8 to 12.3). Musculoskeletal adverse events occurred more often in the exercise group than in the health-education group (in 18.5% vs. 11.5% of patients).
Conclusions: A 3-year structured exercise program initiated soon after adjuvant chemotherapy for colon cancer resulted in significantly longer disease-free survival and findings consistent with longer overall survival. (Funded by the Canadian Cancer Society and others; CHALLENGE ClinicalTrials.gov number, NCT00819208.).
Copyright © 2025 Massachusetts Medical Society.
Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Manual therapy and exercise for rotator cuff disease.Cochrane Database Syst Rev. 2016 Jun 10;2016(6):CD012224. doi: 10.1002/14651858.CD012224. Cochrane Database Syst Rev. 2016. PMID: 27283590 Free PMC article.
-
A systematic overview of chemotherapy effects in colorectal cancer.Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367. Acta Oncol. 2001. PMID: 11441937
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
-
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.N Engl J Med. 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811. N Engl J Med. 2024. PMID: 38959480 Clinical Trial.
Cited by
-
Highlights from the 2025 ASCO Annual Meeting.Nat Cancer. 2025 Jul;6(7):1131-1132. doi: 10.1038/s43018-025-01021-1. Nat Cancer. 2025. PMID: 40634641 No abstract available.
-
Effects of aerobic exercise on body composition and exerkines in colorectal cancer survivors.Front Sports Act Living. 2025 Jun 26;7:1579221. doi: 10.3389/fspor.2025.1579221. eCollection 2025. Front Sports Act Living. 2025. PMID: 40642656 Free PMC article.
-
Exercise as a cancer treatment: New evidence from preclinical and early phase clinical studies.J Sport Health Sci. 2025 Jun 11;14:101066. doi: 10.1016/j.jshs.2025.101066. Online ahead of print. J Sport Health Sci. 2025. PMID: 40513716 Free PMC article. No abstract available.
-
Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Front Cell Dev Biol. 2025 Jul 25;13:1648379. doi: 10.3389/fcell.2025.1648379. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40787624 Free PMC article. Review.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical